Literature DB >> 8035322

Comparison of phosphodiesterase III, IV and dual III/IV inhibitors on bronchospasm and pulmonary eosinophil influx in guinea pigs.

D C Underwood1, C J Kotzer, S Bochnowicz, R R Osborn, M A Luttmann, D W Hay, T J Torphy.   

Abstract

Selective inhibition of phosphodiesterase (PDE) isozymes has been shown to inhibit inflammatory cell function and relax airway smooth muscle and, thus, may be useful in the therapy of asthma. In guinea pigs sensitized to ovalbumin (OA), the effects of three PDE inhibitors were compared: siguazodan (PDE III selective, IC50 = 0.7 microM), rolipram (PDE IV selective, IC50 = 0.8 microM) and zardaverine (dual PDE III/IV, IC50S = 2.5 microM and 1.1 microM, respectively) against histamine-, leukotriene (LT) D4- and OA-induced bronchospasm in vitro and in vivo. Rolipram or zardaverine (0.1-10 microM), but not siguazodan, inhibited OA-induced contraction of the isolated trachea in a concentration-dependent manner. Rolipram or siguazodan alone (10 microM) were ineffective against histamine- or LTD4-induced contractions. Zardaverine alone (10 microM) or the combination of rolipram and siguazodan (10 microM each) markedly antagonized the contractions elicited by both spasmogens. In anesthesized, ventilated guinea pigs, the i.v. ID50S against OA-induced bronchospasm were: rolipram = 0.2 mg/kg, siguazodan > 10 mg/kg and zardaverine = 2.4 mg/kg. When administered at doses up to 7.5 mg/kg, i.v., rolipram or siguazodan were markedly less effective (i.e., < or = 50% inhibition) than zardaverine (ID50S = 2.4 and 1.7 mg/kg, respectively) at blocking exogenous histamine- or LTD4-induced bronchospasm. However, when administered in combination with siguazodan (5.4 mg/kg, i.v.), rolipram (0.4-5.4 mg/kg) abolished histamine- and LTD4-induced bronchoconstriction. In conscious guinea pigs, zardaverine (5 mg/kg, intragastrically (i.g.) or the combination of rolipram and siguazodan (5 mg/kg each) were substantially more effective than rolipram or siguazodan alone at inhibiting aerosol histamine- or LTD4-induced bronchospasm. In the same animals, rolipram or zardaverine (5 mg/kg, i.g.) but not siguazodan (5 mg/kg, i.g.) markedly inhibited aerosol OA-induced bronchoconstriction. The OA-induced pulmonary eosinophil infiltration in these animals was attenuated by all treatments with zardaverine producing the greatest degree of inhibition. These results indicate that 1) PDE IV inhibitors but not PDE III inhibitors are effective at blocking antigen-induced bronchospasm, 2) compounds that selectively inhibit either PDE III or PDE IV are poor inhibitors of bronchoconstriction elicited by exogenously administered spasmogens, and 3) the combined inhibition of both PDE III and PDE IV isozymes acts in an additive or synergistic manner to inhibit bronchospasm in the guinea pig.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8035322

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  21 in total

1.  The effect of isoenzyme-selective PDE inhibitors on methacholine-induced contraction of guinea-pig and rat ileum.

Authors:  A Tomkinson; D Raeburn
Journal:  Br J Pharmacol       Date:  1996-08       Impact factor: 8.739

2.  Inhibition of pulmonary eosinophilia and airway hyperresponsiveness in allergic mice by rolipram: involvement of endogenously released corticosterone and catecholamines.

Authors:  T T Kung; Y Crawley; B Luo; S Young; W Kreutner; R W Chapman
Journal:  Br J Pharmacol       Date:  2000-05       Impact factor: 8.739

3.  Effects of several glucocorticosteroids and PDE4 inhibitors on increases in total lung eosinophil peroxidase (EPO) levels following either systemic or intratracheal administration in sephadex- or ovalbumin-induced inflammatory models.

Authors:  D M Hammerbeck; S M McGurran; P L Radziszewski; E A Egging; D D Johnson; A M Hupperts; G W Gullikson
Journal:  Inflammation       Date:  2000-08       Impact factor: 4.092

Review 4.  Clinical pharmacology of Cilomilast.

Authors:  Geoff Down; Sarah Siederer; Sam Lim; Peter Daley-Yates
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

5.  The effects of phosphodiesterase type 4 inhibitors on tumour necrosis factor-alpha and leukotriene B4 in a novel human whole blood assay.

Authors:  C Brideau; C Van Staden; A Styhler; I W Rodger; C C Chan
Journal:  Br J Pharmacol       Date:  1999-02       Impact factor: 8.739

6.  Effects of selective phosphodiesterase inhibitors on platelet-activating factor- and antigen-induced airway hyperreactivity, eosinophil accumulation, and microvascular leakage in guinea pigs.

Authors:  J L Ortiz; J M Vallés; M Martí-Cabrera; J Cortijo; E J Morcillo
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-01       Impact factor: 3.000

7.  Novel relaxant effects of RPL554 on guinea pig tracheal smooth muscle contractility.

Authors:  R Venkatasamy; D Spina
Journal:  Br J Pharmacol       Date:  2016-07-07       Impact factor: 8.739

8.  Inhibition of bronchospasm and ozone-induced airway hyperresponsiveness in the guinea-pig by CDP840, a novel phosphodiesterase type 4 inhibitor.

Authors:  M Holbrook; N Gozzard; T James; G Higgs; B Hughes
Journal:  Br J Pharmacol       Date:  1996-07       Impact factor: 8.739

9.  Effect of the glucocorticosteroid budesonide and a novel phosphodiesterase type 4 inhibitor CDP840 on antigen-induced airway responses in neonatally immunised rabbits.

Authors:  N Gozzard; A el-Hashim; C M Herd; S M Blake; M Holbrook; B Hughes; G A Higgs; C P Page
Journal:  Br J Pharmacol       Date:  1996-07       Impact factor: 8.739

Review 10.  The efficacy and safety of cilomilast in COPD.

Authors:  Stephen Rennard; Katharine Knobil; Klaus F Rabe; Andrea Morris; Neil Schachter; Nicholas Locantore; Walter G Canonica; Yuanjue Zhu; Frank Barnhart
Journal:  Drugs       Date:  2008       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.